Business
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n June 20, 2025\n \n\n /CNW/ --\n \n\n\n USA\n \n News Group\n \n\n\n News Commentary\n \n – The costs of cancer drugs is skyrocketing, according to a\n \n recent report\n \n from\n \n Bloomberg\n \n . Analysts at\n \n Nova One Advisor\n \n estimate that the\n \n global oncology drugs market\n \n will grow at a 7.4% CAGR through to\n \n US$366.24 billion\n \n by 2034. Help doesn't appear to be coming from the public sector, as\n \n reports\n \n state that the current US administration could\n \n drastically reduce funding\n \n of the\n \n National Cancer Institute (NCI)\n \n by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Immuneering Corporation\n \n (NASDAQ: IMRX),\n \n GRAIL, Inc.\n \n (NASDAQ: GRAL),\n \n Intensity Therapeutics, Inc.\n \n (NASDAQ: INTS), and\n \n Relay Therapeutics, Inc.\n \n (NASDAQ: RLAY).\n \n\n\n\n\n\n\n\n The global oncology market is expected to see strong growth over the next decade, with\n \n ResearchAndMarkets\n \n\n forecasting\n \n it to reach\n \n US$866.1 billion\n \n by 2034 at a 10.8% CAGR. A separate estimate from\n \n Vision Research Reports\n \n\n projects\n \n the market will surpass\n \n US$903.81 billion\n \n by the same year, growing at a 10.9% CAGR.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the\n \n appointment\n \n of\n \n Jared Kelly\n \n as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-onco...